Company / Gross Profit per Share
United Therapeutics Gross Profit per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$62.42
FY2025
5-year range
$35.12 / $62.42
FY2021-FY2025
Trend
+14.4%
vs FY2024
Sector context
#1 of 29
Health Care
What the data says
Among 29 Health Care companies, United Therapeutics is in the top 3% for gross profit per share. Gross Profit per Share has increased for 7 consecutive years, from $7.77 in FY2018 to $62.42 in FY2025.
Based on SEC 10-K filings.
62.42 in FY2025 with a 5-year CAGR of +14.8%. Ranks 1st among 29 companies in Health Care.
Improved from $44.97 to $62.42 over the past 2 years.
Health Care sector context is included.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +16.4%
- 5-Year CAGR
- +14.8%
- 10-Year CAGR
- -
Sector benchmark
+670.3% above sector average
Key checks
Key Insights
- United Therapeutics's gross profit per share has grown for 7 consecutive years.
- In FY2025, gross profit per share increased 14.4% year-over-year.
- Ranks #1 out of 29 companies in the Health Care sector.
- Lowest gross profit per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $62.42 | +14.4% |
| FY2024 | $54.58 | +21.4% |
| FY2023 | $44.97 | +13.7% |
| FY2022 | $39.57 | +12.7% |
| FY2021 | $35.12 | +12.1% |
| FY2020 | $31.34 | +2.6% |
| FY2019 | $30.54 | +293.0% |
| FY2018 | $7.77 | -6.3% |
| FY2017 | $8.29 | +3.0% |
| FY2016 | $8.05 | +23.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026